Encorafenib

Brand Name

Braftovi161-163,#

Pharmacology

Antineoplastic, multikinase inhibitor

FDA Indication

BRAF-positive (V600E or V600K) metastatic melanoma (in combination with binimetinib)

Similars

Dabrafenib, vemurafenib

Further Reading in Goodman & Gilman’s